Home > Journals > Medicine > Hématologie > summary
 
      Advanced search    Shopping cart    French version 
 
Latest books
Catalogue/Search
Collections
All journals
Medicine
Hématologie
- Current issue
- Archives
- Subscribe
- Order an issue
- More information
Biology and research
Public health
Agronomy and biotech.
My account
Forgotten password?
Online account   activation
Subscribe
Licences IP
- Instructions for use
- Estimate request form
- Licence agreement
Order an issue
Pay-per-view articles
Newsletters
How can I publish?
Journals
Books
Help for advertisers
Foreign rights
Book sales agents



 

Texte intégral de l'article
 
Printable version

Regulating interactions between von Willebrand factor and platelets


Hématologie. Volume 18, Number 2, 109-15, Mars-Avril 2012, Revue

Résumé   Texte intégral  

Author(s) : Peter J. Lenting, Frédéric Adam

Summary : The formation of thrombi is a complex process involving many players, including biological agents and physical parameters. Among the several thrombogenic proteins, von Willebrand factor (VWF) plays a major role in the initiation of thrombus formation. This adhesive multimeric protein functions as a molecular bridge between the subendothelial matrix and the platelet glycoprotein (GP) Ib/IX/V complex. Indeed, FVW-GPIb/IX/V interactions allow the recruitment of circulating platelets to the site of injury and the initiation of thrombus formation. VWF also promotes platelet aggregation and thrombus growth by involving platelet integrin α IIbβ 3. Given the co-existence of VWF and platelets in the circulation, this implies that there must be regulatory mechanisms that prevent premature formation of VWF-platelet aggregates that could occlude the vasculature. Indeed, several mechanisms to limit VWF-platelet interactions have been identified (i) at the level of VWF by conformational modifications induced by shear stress\; (ii) by interactions with endothelial proteins (Galectin-1, Galectin-3, osteoprotegerin)\; (iii) by ADAMTS13-mediated proteolysis of very large VWF multimers\; or (iv) by plasma-based inhibitors of VWF-platelet interactions. The current review will provide an overview of novel insights of the regulatory pathways at the level of VWF that are directed to prevent premature binding of VWF to platelets.

Keywords : von Willebrand factor, thrombosis, platelets, ADAMTS13, von Willebrand disease, thrombotic thrombocytopenic purpura

 

About us - Contact us - Conditions of use - Secure payment
Latest news - Conferences
Copyright © 2007 John Libbey Eurotext - All rights reserved
[ Legal information - Powered by Dolomède ]